<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00785317</url>
  </required_header>
  <id_info>
    <org_study_id>080818</org_study_id>
    <nct_id>NCT00785317</nct_id>
  </id_info>
  <brief_title>Effects of Estradiol on Menopausal Breast</brief_title>
  <acronym>BrAVA</acronym>
  <official_title>Effects of Oral 1 mg Oestradiol (E2)/ 2 mg of Drospirenone (DRSP) Compared to Oral 1 mg of Oestradiol (E2)/ 0.5 mg Noresthisterone Acetate (NETA)on the Postmenopausal Breast; a Double Blind Randomized Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects on breast in postmenopausal women
      randomized to either oestradiol in combination with DRSP or E2 in combination with NETA
      during six months.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">April 2010</completion_date>
  <primary_completion_date type="Anticipated">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mammographic breast density - classified according to digitized data-based quantification of breast density.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects on serum levels of Oestradiol etc.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hormone Replacement Therapy</condition>
  <arm_group>
    <arm_group_label>Angemin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Activelle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 mg of oral E2 in continuous combination with 0.5 mg of NETA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angemin vs Activelle</intervention_name>
    <description>1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP or 1 mg of oral E2 in continuous combination with 0.5 mg of NETA during six months.</description>
    <arm_group_label>Angemin</arm_group_label>
    <arm_group_label>Activelle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Naturally postmenopausal, symptomatic, apparently healthy women, with the need for
             hormone therapy aged 50 - 70 years with a BMI &gt;18 and ≤30 kg/m2 and without any
             previous history of breast disease will be recruited for the study.

          -  They should be amenorrheic for at least 12 months or less than 12 months with S- FSH
             values &gt;40 IU/L.

          -  They should be free of any sex hormone treatment for at least three months before
             inclusion.

        Exclusion Criteria:

          -  General contraindications for HT according to Swedish product label. Age &gt;60 years.
             BMI ≤18 or ≥30 kg/m2.

          -  Any previous history of cancer.

          -  Any previous history of breast disease or abnormal mammogram.

          -  In addition: hypertension (systolic BP &gt;160 mm Hg or diastolic &gt;100 mm Hg),
             hyperlipidemia (total cholesterol &gt;8.0 mmol/L or triglycerides &gt;3.0 mmol/L), diabetes
             mellitus, history of thromboembolic disease, heart failure, liver disease or
             porphyria, undiagnosed vaginal bleeding. No sex hormone treatment for at least three
             months before inclusion.

          -  No concomitant treatment known to influence hormone metabolism (warfarin, rifampicin,
             carbamazepine, griseofulvin, hydantoins, primidone, barbiturates, broad spectrum
             antibiotics) is to be accepted.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eva Lundström</last_name>
    <phone>+46851770000</phone>
    <email>eva.lunstrom@karolinska.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eva Lundström</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2008</study_first_submitted>
  <study_first_submitted_qc>November 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2008</study_first_posted>
  <last_update_submitted>November 4, 2008</last_update_submitted>
  <last_update_submitted_qc>November 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2008</last_update_posted>
  <responsible_party>
    <name_title>Eva Lundström, MD, PhD</name_title>
    <organization>Karolinska University Hospital</organization>
  </responsible_party>
  <keyword>Postmenopausal Hormone Replacement Therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

